Versatile Vaccinex Needs A Trial Or Partner Win, But Scaled Down Operation May Be More Likely [Seeking Alpha]
Vaccinex, Inc. (VCNX)
Company Research
Source: Seeking Alpha
SummaryVaccinex has struggled to win over investors since its IPO in Aug 2018 raised $39.6m to further development of its SEMA4D targeting antibody platform and candidates.Its lead candidate Pepinemab has shown promise in both neurology and oncology however - notably as a treatment for Huntington's Disease and non-small cell lung cancer.Its share price spiked to $8.5 in April on positive data from a phase 1/2b trial alongside Merck KGaA's Bavencio for NSCLC, but a registrational trial is not on the table.Funding operations looks to be the company's biggest concern. Cash burn in 2019 was $32m and Vaccinex has only $4.2m of of current assets.Trading at just $3.6, Vaccinex needs a Huntington's trial win to trigger a cash raise, or operations will have to be scaled down. The current low price limits downside. This is a risky opportunity.Investment ThesisTradingViewA review of Vaccinex's (VCNXVaccinex's lead candidate, Pepinemab - an inhibitor of semaphorin 4D ("SEMA4D") is a unique and po
Show less
Read more
Impact Snapshot
Event Time:
VCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCNX alerts
High impacting Vaccinex, Inc. news events
Weekly update
A roundup of the hottest topics
VCNX
News
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Vaccinex Reports 2023 Financial Results and Provides Corporate UpdateGlobeNewswire
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswire
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology [Yahoo! Finance]Yahoo! Finance
VCNX
Sec Filings
- 4/17/24 - Form EFFECT
- 4/16/24 - Form 424B3
- 4/12/24 - Form D
- VCNX's page on the SEC website